Oorsprong van het eerstegraads netwerk van Michael Beckert
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 18 | |
| Public Company | Pharmaceuticals: Major | 12 | |
| Extinct | Pharmaceuticals: Other | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Michael Beckert via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Pharmaceuticals: Major | President | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Secretary Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| HUMANIGEN, INC. | Biotechnology | Sales & Marketing Chairman | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Gilde Investment Management BV
 Gilde Investment Management BV Investment ManagersFinance Gilde Investment Management BV is an Independent Private Equity firm founded in 1982. Gilde Investment Management BV is headquartered in Utrecht. | Investment Managers | Private Equity Investor | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| State University of New York College at Geneseo | College/University | Undergraduate Degree | |
| State University of New York at Buffalo | College/University | Doctorate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Maine | College/University | Graduate Degree | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| University of Copenhagen | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| Erasmus University Rotterdam | College/University | Graduate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
| University of Southern Denmark | College/University | Undergraduate Degree Graduate Degree Doctorate Degree | |
PricewaterhouseCoopers (Denmark)
 PricewaterhouseCoopers (Denmark) Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., PricewaterhouseCoopers (Denmark) is a company based in Hellerup, Denmark. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Gilde Healthcare Partners BV
 Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Investment Managers | Chief Executive Officer | |
| ADOCIA | Pharmaceuticals: Major | Founder Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member | |
Gilde Healthcare Holding BV
 Gilde Healthcare Holding BV Financial ConglomeratesFinance Gilde Healthcare Holding BV is an investment holding Dutch company. The private company is based in Utrecht, NL. and has subsidiaries in Australia, Netherlands, United States and Germany. The CEOs of the company are Edwin William de Graaf, Marc Olivier Perret. | Financial Conglomerates | Chief Executive Officer | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member | |
| Life Cycle Pharma A/S | Director/Board Member Chairman Chief Executive Officer | ||
| UNIQURE N.V. | Biotechnology | Director/Board Member | |
| SYNAPTOGENIX, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman Director of Finance/CFO | |
| Columbia Business School | College/University | Masters Business Admin | |
Wavodyne Therapeutics, Inc.
 Wavodyne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wavodyne Therapeutics, Inc. develops and commercializes novel small molecule therapeutics for the treatment of memory and cognitive disorders resulting from neuro-inflammatory processes. The firm also provides research and development services. The company was founded by Jim New and is headquartered in Rochester, NY. | Pharmaceuticals: Major | Chief Executive Officer | |
| ITERUM THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Chairman | |
Searle Pharmaceuticals Pvt Ltd.
 Searle Pharmaceuticals Pvt Ltd. Pharmaceuticals: MajorHealth Technology Searle Pharmaceuticals Pvt Ltd. is a Pakistani company that manufactures pharmaceuticals. The private company is based in Bahawalpur, Pakistan. The CEO of the company is Zubair Razzak Palwala. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CESSATECH A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Ascendis Pharma Bone Diseases A/S | Chief Executive Officer Chairman | ||
| Ascendis Pharma Growth Disorders AS | Chief Executive Officer Chairman | ||
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member Chairman | |
| DURATA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer |
Statistieken
Internationaal
| Verenigde Staten | 22 |
| Denemarken | 13 |
| Nederland | 9 |
| Zwitserland | 2 |
| Duitsland | 2 |
Sectoraal
| Health Technology | 30 |
| Consumer Services | 10 |
| Finance | 6 |
| Commercial Services | 5 |
Operationeel
| Director/Board Member | 194 |
| Corporate Officer/Principal | 68 |
| Independent Dir/Board Member | 57 |
| Chairman | 56 |
| Chief Executive Officer | 42 |
Sterkste connecties
| Insiders | |
|---|---|
| James Healy | 50 |
| Jonathan Silverstein | 42 |
| Flemming Ørnskov | 34 |
| Albert Cha | 30 |
| Paul Edick | 27 |
| Martin Olin | 25 |
| Michael Wolff Jensen | 23 |
| Jean Deleage | 23 |
| Kurt Anker Nielsen | 18 |
| Jonathan Leff | 14 |
| James New | 14 |
| Edwin de Graaf | 14 |
| Jan Mikkelsen | 13 |
| Thomas Soloway | 12 |
| Torben Nissen | 12 |
- Beurs
- Insiders
- Michael Beckert
- Bedrijfsconnecties
